ChimerisMonitor

The intuitive software for automated chimerism analysis

Features

  • Simplifies and speeds up data analysis for BIOTYPE chimerism kits
  • Automates critical and time-consuming steps from allelic call to chimerism value calculation
  • Includes an extensive control concept for run and sample validation
  • Builds a patient database encompassing preTx genotypes and postTx chimerism kinetics
  • Available in 2 product variants:
    ChimerisMonitor IVD with an IVD-certified workflow for robust and reliable data analysis
    ChimerisMonitor RUO for reanalysis of critical data sets outside the IVD-certified workflow

The software is available as the IVDR-compliant ChimerisMonitor IVD application, which, in combination with the Mentype® Chimera® and Mentype® DIPscreen assays, offers a complete IVD-certified workflow from PCR set-up to data analysis. The ChimerisMonitor RUO software can additionally be used to analyze the Mentype® DIPquant assays and critical data sets with, for example, alternative sample types. By installing both applications, a synchronized database is created, which reduces effort and still provides a clear differentiation between the data from both software.

Product Specifications

  • Assays analyzed
  • Mentype® Chimera®, Mentype® DIPscreen, Mentype®DIPquant*
  • Status
  • CE-IVD or For research use only (RUO)*
  • Data input
  • fsa/hidfiles, txt files
  • Data visualizing
  • Electropherogram, calculation results, overview about results in 1 sample sheet, PDF report with longitudinal chimerism kinetics
  • Data processing
  • Database included for saving of pre-transplant and post-transplant data
  • Turnaround time
  • 5 min per sample

Product References

  1. Al-Akioui Sanz, K. et al. Familial CD45RA– T cells to treat severe refractory infections in immunocompromised patients. Front. Med. 10. https://doi.org/10.3389/fmed.2023.1083215 (2023)
  2. Ferreras, C. et al. Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210). Cytotherapy 26, 25-35, https://doi.org/10.1016/j.jcyt.2023.10.002 (2024)
  3. Pérez-Martínes, A. et al. Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE). EClinicalMedicine 39. https://doi.org/10.1016/j.eclinm.2021.101086 (2021)

Resources

Instructions for Use / Handbooks
No items found.
Safety Data Sheets / Non-Hazardous Statements
No items found.
Non Hazardous Statements
No items found.
Technical Information
No items found.
Additional Resources

Ordering Information

ChimerisMonitor IVD

Cat. No.: 46-14800-0000
Status: CE-IVD


ChimerisMonitor RUO

Cat. No.: 46-14801-0000
Status: RUO*


*RUO - Research Use Only products must be validated by the customer with clinically relevant material for diagnostic purposes.

Product Request